Nonpeptidic quinazolinone derivatives as dual nucleotide-binding oligomerization domain-like receptor 1/2 antagonists for adjuvant cancer chemotherapy
Nonpeptidic quinazolinone derivatives as dual nucleotide-binding oligomerization domain-like receptor 1/2 antagonists for adjuvant cancer chemotherapy
复制标题
非肽喹唑啉酮衍生物作为双核苷酸结合寡聚结构域样受体 1/2 拮抗剂用于辅助癌症化疗
DOI：
10.1016/j.ejmech.2020.112723
复制
发表时间：
2020-12-01
影响因子：
6.7
通讯作者：
Liu, Gang
中科院分区：
文献类型：
--
作者：
Ma, Yao;Yang, Jingshu;Liu, Gang
核苷酸结合寡聚化结构域蛋白1和2（NOD 1/2）受体是潜在的免疫检查点。在这篇文章中，喹唑啉酮衍生物（36 B）作为NOD 1/2的双重拮抗剂，显着敏感的B16荷瘤小鼠紫杉醇治疗，通过抑制核因子κ B（NF-κ B B）和丝裂原活化蛋白激酶炎症信号传导，由NOD 1/2介导。(C)2020 Elsevier Masson SAS。All rights reserved.
Nucleotide-binding oligomerization domain-containing protein 1 and 2 (NOD1/2) receptors are potential immune checkpoints. In this article, a quinazolinone derivative (36b) as a NOD1/2 dual antagonist was identified that significantly sensitizes B16 tumor-bearing mice to paclitaxel treatment by inhibiting both nuclear factor kappa B (NF-kappa B) and mitogen-activated protein kinase inflammatory signaling that mediated by NOD1/2. (C) 2020 Elsevier Masson SAS. All rights reserved.